Exbio — Research products — Antibodies — Nucleus — Anti-p53 Purified

Anti-p53 Purified

Regulatory status

RUO

Antigen

p53

Clone

BP53-12

Format

Purified

Reactivity

Human, Non-human primates

Application

ELISA, IP, WB, FC (QC tested), IHC-P, ICC

Variant

0.1 mg

11-114-C100

In stock

154.00 USD

0.025 mg

11-114-C025

Delivery 1 week

77.00 USD

Variant

0.1 mg

11-114-C100

In stock

154.00 USD

0.025 mg

11-114-C025

Delivery 1 week

77.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG2a

Specificity

The antibody BP53-12 recognizes a defined epitope (aa 16-25) on human p53, a 50 kDa intracellular tumour suppressor found in increased amounts in a wide variety of transformed cells; it is frequently mutated or inactivated in many types of cancer.

Application

ELISA, IP, WB, FC (QC tested), IHC-P, ICC

Application details

Western blotting: Recommended dilution: 1-2 μg/ml, overnight at 4°C; positive control: RAMOS human lymphoma cell line, non-reducing conditions. SDS-PAGE (12% separating gel).
Immunohistochemistry: Recommended dilution: 5-10 μg/ml.
Flow cytometry: Recommended dilution: 1-4 µg/ml. Intracellular staining.

Reactivity

Human, Non-human primates

Immunogen

Bacterially expressed full-length wild-type p53

Concentration

1 mg/ml

Preparation

Purified by sequential steps of physicochemical fractionation (differential precipitation and solid-phase chromatography methods).

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

BCC7, TRP53, TP53, LFS1

Antigen description

The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nukleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization.

Entrez Gene ID 7157

UniProt ID P04637

Immunocytochemistry (confocal microscopy) of human HeLa cells using anti-p53 (BP53-12; FITC). The expression of p53 protein was enhanced by intercalating reagent. Cells were fixed and permeabilized before incubation with the p53-FITC MAb. Photo provided by Dr. Hodný, Inst. of Experimental Medicine, Prague, Czech Republic

Separation of Ramos cells stained using anti-human p53 (BP53-12) purified antibody (concentration in sample 1,7 μg/ml, GAM APC, red-filled) from Ramos cells unstained by primary antibody (GAM APC, black-dashed) in flow cytometry analysis (intracellular staining).

General references:

Agarwal ML, Agarwal A, Taylor WR, Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8493-7.
PubMed

Agarwal ML, Agarwal A, Taylor WR, Chernova O, Sharma Y, Stark GR: A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14775-80.
PubMed

Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schönthal AH, Katula KS, Stark GR: Mechanisms of G2 arrest in response to overexpression of p53. Mol Biol Cell. 1999 Nov;10(11):3607-22.
PubMed

Taylor WR, Agarwal ML, Agarwal A, Stacey DW, Stark GR: p53 inhibits entry into mitosis when DNA synthesis is blocked. Oncogene. 1999 Jan 14;18(2):283-95.
PubMed

Tanigawa S, Fujii M, Hou DX: Stabilization of p53 is involved in quercetin-induced cell cycle arrest and apoptosis in HepG2 cells. Biosci Biotechnol Biochem. 2008 Mar;72(3):797-804.
PubMed

Product specific references:

Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991 Sep;6(9):1699-703.
PubMed

Bartkova J, Bartek J, Lukas J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Midgley CA, Lane DP: p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int J Cancer. 1991 Sep 9;49(2):196-202.
PubMed

Rössner P Jr, Binková B, Chvátalová I, Srám RJ: Acrylonitrile exposure: the effect on p53 and p21(WAF1) protein levels in the blood plasma of occupationally exposed workers and in vitro in human diploid lung fibroblasts. Mutat Res. 2002 May 27;517(1-2):239-50.
PubMed

Dolezalova H, Vojtesek B, Kovarik J: Epitope analysis of the human p53 tumour suppressor protein. Folia Biol (Praha). 1997;43(1):49-51.
PubMed